In This Section

Program: Wednesday, July 22

Tuesday, July 21 Thursday, July 23 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, July 22

Wednesday, July 22

Networking Breakfast

7-8 a.m. | Independence Ballroom West

Fireside Chat

8-8:45 a.m. | Grand Ballroom

  • 8:05 a.m. | Fireside Chat
    Richard Pazdur

Break

8:45-9 a.m. | Grand Ballroom Prefunction

Plenary Sessions 1-2

9-11 a.m.

Plenary Session 1: Drug Discovery – Pharma vs Biotech vs Academia

Grand Ballroom
Session Chair: William Pao, Revelio Therapeutics, Inc., New York, New York

  • 9:05 a.m. | Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:35 a.m. | Lilli Petruzzelli, Genentech, Inc., South San Francisco, California
  • 10:05 a.m. | James Christensen, Terremoto Biosciences, South San Francisco, California
  • 10:35 a.m. | Panel Discussion

Plenary Session 2: Technologies, Biomarkers, and Advanced Diagnostics to Guide Target Discovery and Effective Anti-cancer Therapies

Constitution Ballroom A
Session Chair: Kurt A. Schalper, Yale University, New Haven, Connecticut

  • 9:05 a.m. | Advances and impact of circulating molecular biomarkers in oncology drug development
    Maximilian Diehn, Stanford University, Stanford, California
  • 9:30 a.m. | Single-cell molecular analysis of malignant and non-malignant cells to support therapeutic selection and monitoring in cancer patients
    Kellie N. Smith, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 9:55 a.m. | Speaker to be announced
  • 10:20 a.m. | Interpretable image analysis using advanced computational models to support therapeutic decisions in oncology
    Issam El Naqa, Moffitt Cancer Center, Tampa, Florida
  • 10:45 a.m. | Panel Discussion

Break

11-11:20 a.m. | Grand Ballroom Prefunction

Drugging the Undruggable Sessions 1-3

11:20 am-12:50 p.m.

Drugging the Undruggable Session 1: Epigenetics

Grand Ballroom
Session Chair: Johnathan R. Whetstine, Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • 11:25 a.m. | Jian Jin, Icahn School of Medicine at Mount Sinai, New York, New York
  • 11:45 a.m. | KDM therapies and ecDNA amplification control
    Johnathan R. Whetstine
  • 12:05 p.m. | Scott A. Armstong, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 2: Transcription Factors

Constitution Ballroom A
Session Chair: Angela N. Koehler, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • 11:25 a.m. | multiple TFs, FOXA1
    Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • 11:45 a.m. | Speaker to be announced
  • 12:05 p.m. | Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 3: Synthetic Lethality Beyond DDR

Constitution Ballroom B
Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 11:25 a.m. | Novel synthetic lethal targets
    Mathew J. Garnett, Wellcome Sanger Institute, Cambridge, United Kingdom
  • 11:45 a.m. | Synthetic lethality opportunities for MMEJ-deficient tumors
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:05 p.m. | Kathryn C. Arbour, Memorial Sloan Kettering Cancer Center, New York, New York
  • 12:25 p.m. | Panel Discussion

Lunch on Own

12:50-3 p.m.

Challenges in Drug Discovery Sessions 1-3

3:15-5 p.m.

Challenges in Drug Discovery Session 1: Biology

Grand Ballroom
Session Chair: Paul Workman, The Institute of Cancer Research, London, United Kingdom

  • 3:20 p.m. | Integrated bioscience solutions to drug discovery challenges
    Paul Workman
  • 3:50 p.m. | Application of genetic approaches to drug discovery
    Jason M. Sheltzer, Stanford University, Stanford, California
  • 4:20 p.m. | Short talk selected from proffered abstracts
  • 4:40 p.m. | Panel Discussion

Challenges in Drug Discovery Session 2: Chemistry

Constitution Ballroom A
Session Chair: Kevan Shokat, University of California, San Francisco, California

  • 3:20 p.m. | Kevan Shokat
  • 3:50 p.m. | Speaker to be announced
  • 4:20 p.m. | Short talk selected from proffered abstracts
  • 4:40 p.m. | Panel Discussion

Challenges in Drug Discovery Session 3: Clinical

Constitution Ballroom B
Session Chair: Matthew D. Hellmann, AstraZeneca, Gaithersburg, Maryland

  • 3:20 p.m. | Speaker to be announced
  • 3:50 p.m. | Delivering on precision medicine: Navigating biological purity with operational and commercial realities
    Alice T. Shaw, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:20 p.m. | Short talk selected from proffered abstracts
  • 4:40 p.m. | Panel Discussion

Poster Session A / Reception

5:15-7:45 p.m. | Back Bay Ballroom

Evening off / Dinner on own

7:45 p.m.